跳至主要内容
临床试验/CTRI/2023/11/059941
CTRI/2023/11/059941招募中4 期

An Open label, Prospective, Single Arm, Multicenter, Real-world Active Post-Marketing Surveillance Study to Evaluate Safety and Efficacy of Tofacitinib Ointment 2% w/w in Adult Mild to Moderate Atopic Dermatitis Patients having Flare-up of Disease - NI

Intas Pharmaceuticals Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Male and female patients, with age = 18 years, willing to give voluntary informed consent
  • 2.Have a clinical diagnosis of atopic dermatitis(AD) according to the criteria of Hanifin and Rajka
  • 3.Patients with mild to moderate AD based on vIGA-AD score of 2 (mild) or 3 (moderate) at Baseline
  • 4.Have involvement of = 5% treatable body surface area (BSA) (excluding the scalp) and up to and including 20% of total BSA at Day 1 using Mostellar formulae
  • 5.Eligible patient prescribed tofacitinib 2% w/w ointment, in usual course of treatment as per PI discretion

排除标准

  • 1.Having no contraindications as mentioned in prescribing information
  • 2.Any other condition where PI assesses that patient is not eligible for participation in the study

研究者

相似试验